TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of asthma~* History of asthma medication use during the 2005 fall ragweed season~* Suspected ragweed allergy~* Positive laboratory tests for ragweed allergy~Exclusion Criteria:~* Received immunotherapy for ragweed or other allergens within the 5 years prior to study entry~* Received anti-IgE (omalizumab) within the year prior to study entry~* 3 or more courses of oral corticosteroids for asthma within the year prior to study entry~* Inpatient hospitalization for asthma within the 5 years prior to study entry~* History of respiratory failure or intubation for asthma~* Smoking within the 6 months prior to study entry~* Greater than 5 pack/year history of smoking~* Clinically significant acute or chronic illness~* Chronic immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Association Between the Transfer of Lactobacilli From the Gastrointestinal Tract to the Vagina and the Prevention / Eradication of Abnormal Vaginal Flora in High Risk Pregnancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women from at least 13 weeks of gestation with a risk factor for preterm labor~Exclusion Criteria:~* Women with preterm premature rupture of the membranes~* Immunocompromised women~* Planned elective preterm birth for reasons other than preterm premature rupture of membranes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primary prevention - Urex Plus (Type: EXPERIMENTAL): Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
- Primary prevention - Placebo (Type: PLACEBO_COMPARATOR): Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
- Secondary prevention - Urex Plus (Type: EXPERIMENTAL): Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
- Secondary prevention - Placebo (Type: PLACEBO_COMPARATOR): Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
- Eradication - Urex Plus (Type: EXPERIMENTAL): Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
- Eradication - Placebo (Type: PLACEBO_COMPARATOR): Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
- Lactobacilli transfer - probiotic capsule (Type: OTHER): Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
- Lactobacilli transfer - probiotic capsule after 2 months (Type: OTHER): Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Value of Ankle Pressure Index After Maximal Exercise Tests

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old and more~Exclusion Criteria:~* patient with recent cardiovascular event

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Exercise test (Type: OTHER): Ankle pressure Index measure before and after Maximal Exercise Tests

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous pregnant women between the ages of 18 and 45 years with low risk pregnancies who present for obstetrical ultrasound at 36 weeks of gestation or later with a planned delivery at a Perinatal Research Consortium hospital.~Exclusion Criteria:~* Multifetal pregnancy at the time of presentation~* Known fetal chromosomal anomaly~* Known fetal malformation~* Preeclampsia~* Fetal growth restriction~* Multiparity~* Prior cesarean section~* Placental abnormalities such as previa or accreta~* Pregestational diabetes~* Plan to deliver outside the Perinatal Research Consortium affiliated hospitals

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CPR less than the 10%le (Type: None): Group of patients with fetuses with cerebroplacental ratio less than 10%le
- CPR greater or equal than 10%le (Type: None): Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Epidural Morphine on Shoulder Pain Following Thoracotomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 to 75 years~* Scheduled for an elective thoracotomy~* Physical status 1-3~Exclusion Criteria:~* Contraindication to epidural analgesia (coagulopathy, sepsis or local infection at the site of injection, spinal deformity, previous major spinal thoracic surgery)~* A known allergy to local anesthetics, acetaminophen, fentanyl or morphine.~* Pre-existing shoulder pain ipsilateral to the surgery~* Pre-existing chronic pain~* Current use of opioids~* Recent history of alcohol or drug abuse.~* The inability to understand a verbal numerical pain scale (VNPS) despite previous instruction~* Severe renal insufficiency~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fentanyl (Type: ACTIVE_COMPARATOR): Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
- Morphine (Type: EXPERIMENTAL): Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 65 or older.~* Newly diagnosed cancer.~* Referred to the geriatrics service for pre-operative evaluation before surgical resection of his/her tumor.~Exclusion Criteria:~* Inability to comprehend English.~* Deafness , measured by the Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S) \[16\], score equal or above 30. (appendix 5)~* Cognitive impairment (score of 0-1 in Mini-Cog Test).~* Nursing home resident.~* Planned hospital length of stay of one day or less.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: None): The patient will get instructions on: - Follow-up appointment date/time with your surgeon - Proper diet - Medications - Communicating concerning symptoms with the surgeon~The patient will answer questions on:~* Social support~* Quality of life
- Phone Calls (Type: None): In addition to what the usual care group gets, the patient will also receive weekly phone calls by a geriatrics RN following hospital discharge.~The patient will answer questions on:~* Social support~* Quality of life

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Deescalating Carbapenems in Hospital Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Hospitalization in conventional ward; (3) Receiving a curative treatment with a carbapenem for at least 24 hours and less than 3 days for a recent infection due to an ESBL-PE, either initially or secondary documented~* With a site of infection originating from the urinary, digestive or biliary tract~* Identification of an ESBL-PE for which susceptibility results (by the method of discs) have shown to be susceptible to more narrow spectrum beta-lactams (cephalosporins, b-lactamase inhibitors, monobactams)~* With sepsis signs and symptoms controlled after initiation of antibiotic therapy~* For a community-acquired or hospital-acquired infection.~Exclusion Criteria:~* Pregnancy or breastfeeding~* Neutropenia (PNN \< 500/mm3)~* Hospitalization in intensive care unit or bone marrow transplant unit~* Documented polymicrobial infection~* Culture of an ESBL-PE susceptible to an orally active drug (such as fluoroquinolones, cotrimoxazole) and possible use of one of these drugs~* Need to treat a EBLSE infection(s) wtih more than drug other than carbapenems~* Need to maintain an association with an aminoglycoside~* Colonization without signs and symptoms of sepsis~* Sepsis signs and symptoms not controlled at the time of enrolment~* Known allergy to beta-lactams~* Failure to complete medical examination~* Absence of signed written consent.~* Patient without healthcare insurance (French social security, CMU or AME)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Maintaining carbapenem therapy (Type: ACTIVE_COMPARATOR): Intravenous therapy, Maintaining carbapenem therapy
- Deescalation therapy (Type: ACTIVE_COMPARATOR): Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TRAIN Your Sleep; Treating Adolescent Insomnia With Cognitive Behavioral Therapy for Insomnia (CBT-I)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Youth Inclusion Criteria:~* Aged 12 to 17 years.~* Meets criteria for insomnia with or without comorbid chronic musculoskeletal pain.~* Parent/guardian available to provide consent.~* Patient and a primary caregiver are able to independently read and understand English well enough to provide informed consent and complete study procedures.~* Access to email, internet, and audio and video call capabilities.~Parent/Guardian Inclusion Criteria:~* Parent/legal guardian of a child meeting above eligibility criteria~* Able to independently read and understand English well enough to provide informed consent and complete study questionnaires.~Youth Exclusion Criteria:~* History of cardiac or neuromuscular disorder~* Parent-report of child's use of Opioid medications (i.e., fentanyl, morphine, hydromorphone, methadone, hydrocodone, oxycodone) that cannot be discontinued for 7 days prior to study visits.~* Inadequate proficiency in English or a developmental disability that interferes with informed consent/assent or completion of study procedures.~* History of obstructive sleep apnea, restless leg syndrome, or narcolepsy.~* History of bipolar disorder and/or manic episodes~* Diagnosis of epilepsy.~* Currently in foster care or considered a ward of the state.~* History of Raynaud Syndrome.~* Active suicidal ideation, intent or plan in the past month.~Parent Exclusion Criteria:~• Inadequate proficiency in English or a developmental disability that interferes with informed consent or completion of questionnaires.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- CBT-I (Type: EXPERIMENTAL): 5-weekly Cognitive Behavioral Therapy for Insomnia group therapy sessions conducted virtually.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with newly diagnosed brain metastases~* Patient with cancer regardless of the type of primary cancer, with anatomopathological proof~* At least, one measurable lesion ≥ 10 mm on the MRI T1 gadolinium sequences~* Number of brain metastases lower or equal to 5~* Indication of radiosurgery treatment~* Age ≥ 18 years old~* ECOG-PS 0-2~* Expected survival \> 3 months~* Ability to complete self-administered questionnaires. If the patient has a motor disability (hemibody deficit) that does not allow to complete himself the questionnaires, these will be read by a CRA of the Neurosurgery department who will outline the questions without making any comment.~* A non-opposition form must have been completed by the patient~Exclusion Criteria:~* Previous cancer (\< 5 years) except of carcinoma of cervix uteri, basal cell or squamous cell skin carcinoma adequately treated~* Previous brain radiotherapy~* Neurological pathology with cognitive disorders existing before the study~* Having a contraindication for MRI~* Associated leptomeningeal disease~* Patients having another severe or uncontrolled pathology which could compromise the participation at the study (such as infection, cardiovascular, digestive, renal or pulmonary disease)~* Pregnant or breastfeeding woman. The women must not breastfeed for at least 6 months~* Impossibility to submit to the medical examinations of the study due to geographic, social or mental reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- questionnaire administration (Type: EXPERIMENTAL): Quality of life questionnaires administration (EORTC QLQ C30 and BN20 / IADL / HADS / MoCa Edmonton Symptom Assessment Scale)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Orthostatic Hypotension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with severe orthostatic hypotension and other autonomic symptoms who do not meet criteria for one of our standard diagnoses~* non-smokers~* drug-free~* able to give informed consent~* free of pulmonary, renal, hematopoietic, hepatic and cardiac disease~Exclusion Criteria:~* medications affecting the autonomic nervous system~* any chronic illness (cardiac, pulmonary, endocrine, gastrointestinal, rheumatologic)~* anemia (Hct \< 30)~* women of childbearing age who are pregnant or nursing~* smokers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Droxidopa (Type: EXPERIMENTAL): Patients with known or suspected Dopamine beta-Hydroxylase Deficiency were administered Droxidopa doses of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg or 300 mg up to three times daily. Supine and upright blood pressures were subsequently measured 60 to 240 minutes post-dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- suspected CAD for which an indication to PCI is given: both patients with stable CAD, and stable post-acute coronary syndromes (ACS), both with ST-segment elevation (STEMI) and without ST-segment elevation (NSTE-ACS) patients, provided that markers of myocardial necrosis (CK-MB, troponins) are stabilized (i.e., with variations \<20% in two consecutive measurements obtained at ≥6 h time distance before PCI, according to the universal definition of peri-procedural myocardial infarction).~Exclusion Criteria:~* any previously known increase in liver enzymes (AST, ALT) ascribed to liver dysfunction at baseline;~* history of liver toxicity or myopathy on previous treatment with statins;~* left ventricular ejection fraction \<30%;~* renal insufficiency, with creatinine \>2 mg/dL at baseline;~* ongoing treatment with high-dose statins (atorvastatin 80 mg/d or rosuvastatin 40 mg/d);~* pregnant or lactating women.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- twice placebo before PCI (Type: PLACEBO_COMPARATOR): None
- atorvastatin 80 + 40 mg pre PCI (Type: EXPERIMENTAL): None
- rosuvastatin 40 + 40 mg before PCI (Type: EXPERIMENTAL): None
- rosuvastatin 5 + ezetimibe 10 mg twice before PCI (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Unresectable and/or metastatic GIST~* Currently receiving imatinib 400 mg per day for a minimum of 4 weeks prior to registration, and for no more than 6 months prior to registration. This must be the first time that the patient has been treated for metastatic and/or unresectable GIST~* For patients who received imatinib following surgery at the time of an initial diagnosis of GIST, there must be a 6 month interval between completion of imatinib and the diagnosis of metastatic GIST~* Good physical functioning (ECOG Performance Status of 0 or 1)~* Generally, good function of organ such as liver and kidneys~Exclusion Criteria:~* Disease progression during adjuvant therapy with imatinib (adjuvant treatment is treatment that is given after surgery for GIST)~* Known intolerance of imatinib at a dose of 400 mg/day or higher~* Prior systemic therapy for advanced GIST with imatinib or those who have been on imatinib for longer than 6 months for unresectable and/or metastatic disease~* Major surgery within 2 weeks prior to Day 1 of study or who have not yet recovered from prior surgery~* Use of coumadin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)~* Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation \< 2 weeks or who have not recovered from side effects of this therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Patients with blood level less than 1100 will continue imatinib 400 mg daily
- Arm B (Type: ACTIVE_COMPARATOR): Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
- Arm C (Type: ACTIVE_COMPARATOR): Patients with blood level ≥1100 will continue imatinib 400 mg daily
- Arm D (Type: ACTIVE_COMPARATOR): Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* early breast cancer treated with lumpectomy~* must have T1-2 N0-1 invasive carcinoma of the breast~* must sign an informed consent~* must be at least 18 years of age~Exclusion Criteria:~* collagen vascular disease~* metastatic disease~* pregnant or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues